SLC5A2 and heart failure: In brief, SOLOIST-WHF is significant and impacts clinical practice as it was the first trial to show that SGLT2/1 inhibitors are effective and safe for use in those with T2DM, reduced or preserved ejection fraction heart failure, and recent heart failure admission.